SCHEMBL1786940

SCHEMBL1786940

O=C(C[C@@H]1C[C@@H]2CC[C@H]1C2)Nn1nc(-c2ccc(F)cc2)c2ccccc2c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
THRB P10828 1/20 0.42
PKM P14618 1/20 0.42
BLM P54132 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
HPGD P15428 1/20 0.40
LMNA P02545 2/20 0.40
MCHR1 Q99705 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RECQL P46063 1/20 0.38
P2RX7 Q99572 1/20 0.38
CHRNA7 P36544 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1791227 1.00 MAPT (0.45) MAPTALDH1A1KDM4ESMN1; SMN2TDP1
SCHEMBL1791226 1.00 MAPT (0.45) MAPTALDH1A1KDM4ESMN1; SMN2TDP1
SCHEMBL30794868 1.00 MAPT (0.45) MAPTALDH1A1KDM4ESMN1; SMN2TDP1
SCHEMBL1786942 1.00 MAPT (0.45) MAPTALDH1A1KDM4ESMN1; SMN2TDP1
SCHEMBL1786886 0.90 ALDH1A1 (0.43) MAPTALDH1A1SMN1; SMN2TDP1HPGD
SCHEMBL1787773 0.90 MAPT (0.46) MAPTALDH1A1TDP1TP53POLB
SCHEMBL1787776 0.90 MAPT (0.46) MAPTALDH1A1TDP1TP53POLB
SCHEMBL1786888 0.90 ALDH1A1 (0.43) MAPTALDH1A1SMN1; SMN2TDP1HPGD
SCHEMBL1789439 0.90 KDM4E (0.43) MAPTALDH1A1KDM4ETP53POLB
SCHEMBL1791523 0.90 KDM4E (0.43) MAPTALDH1A1KDM4ETP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629143-B2 Potassium channel modulators ABBVIE INC. (US) 2014-01-14 US claimed
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-05-26 US claimed
US-8629143-B2 Potassium channel modulators ABBVIE INC. (US) 2014-01-14 US disclosed
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNQ3 MAPT 3480/4885ALDH1A1 1644/4885KDM4E 574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.